secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2024-04-12T23:59:59+00:00
Accession:  0001493152-24-014380
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 1.01, 2.02, 7.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte raises $15.8M in private placement; FY2023 revenue $1.5M, ops loss $25.1M
--------------------------------------------------------------------------------

- Private placement of 5.1M shares + pre-funded warrants for 342k shares at $2.92/share; gross proceeds ~$15.8M.
- Expected close April 15, 2024; $5M of proceeds to redeem Series A Preferred Stock; remainder for working capital.
- FY2023 revenue $1.5M (+57%); operating loss $25.1M (+40%); cash burn Q4 2023 $4.4M, Q1 2024 est. $3.8M.
- Bio-Rad partnership for transplant monitoring IP; GraftAssure product launch on track for Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315224014380/0001493152-24-014380-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315224014380/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-014380

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer